(-0.41%) 5 460.48 points
(-0.12%) 39 119 points
(-0.71%) 17 733 points
(-0.34%) $81.46
(-3.13%) $2.60
(0.01%) $2 336.90
(0.61%) $29.44
(0.28%) $1 009.00
(-0.06%) $0.933
(0.45%) $10.68
(-0.05%) $0.791
(0.86%) $85.73
0.00% $ 0.0200
Live Chart Being Loaded With Signals
PAVmed Inc. operates as a medical device company in the United States. The company\'s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett\'s Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay...
Stats | |
---|---|
Dzisiejszy wolumen | 15 400 |
Średni wolumen | 0 |
Kapitalizacja rynkowa | 7.23M |
EPS | $-1.750 ( Q1 | 2024-05-13 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 43.86 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-05-04 | O'neil Shaun | Sell | 25 935 | Common stock |
2022-02-22 | O'neil Shaun | Sell | 0 | Common stock |
2022-02-22 | O'neil Shaun | Sell | 195 108 | Employee stock option (right to buy) |
2022-02-22 | O'neil Shaun | Sell | 100 000 | Employee stock option (right to buy) |
2022-02-22 | O'neil Shaun | Sell | 75 000 | Employee stock option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 14 transactions |
Buy: 2 950 000 | Sell: 396 043 |
PAVmed Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
PAVmed Inc Finanse
Annual | 2023 |
Przychody: | $2.45M |
Zysk brutto: | $-6.90M (-281.40 %) |
EPS: | $-8.87 |
FY | 2023 |
Przychody: | $2.45M |
Zysk brutto: | $-6.90M (-281.40 %) |
EPS: | $-8.87 |
FY | 2022 |
Przychody: | $377 000 |
Zysk brutto: | $-3.24M (-858.62 %) |
EPS: | $-17.06 |
FY | 2021 |
Przychody: | $500 000 |
Zysk brutto: | $-85 000.00 (-17.00 %) |
EPS: | $-1.150 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
PAVmed Inc
PAVmed Inc. operates as a medical device company in the United States. The company\'s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett\'s Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej